Use of Dapagliflozin in Primary Prevention of Cardiotoxicity of Anthracycline Chemotherapy in Breast Cancer Patients

NCT07245069 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

100

Enrollment

OTHER

Sponsor class

Conditions

Heart Failure
Anthracycline-induced Cardiac Toxicity
Endothelial Function (FMD)
Arterial Stiffness
Breast Cancer

Interventions

DRUG: Dapagliflozin 10 mg
DRUG: Placebo

Sponsor

University Medical Centre Ljubljana